Eidos Therapeutics to Host Conference Call and Webcast to Discuss ATTR-CM Phase 3 Trial (ATTRibute-CM) Design
February 25 2019 - 8:00AM
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage
biopharmaceutical company focused on addressing the large and
growing unmet need caused by transthyretin (TTR) amyloidosis
(ATTR), today announced that it will host an investor webcast
presentation on Wednesday, February 27, 2019 at 8:00 a.m. ET (5:00
a.m. PT). Management will provide details on the design of the
company’s Phase 3 ATTRibute-CM clinical program studying AG10 in
subjects with ATTR cardiomyopathy and provide a business update.
Conference call and webcast
To participate in the conference call, dial +1-844-293-0174
(U.S. toll free) or 1-916-582-3546 (international), conference ID
7365928. The webcast will be available live and for replay on the
company’s website at ir.eidostx.com.
About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company
focused on addressing the large and growing unmet need in diseases
caused by transthyretin (TTR) amyloidosis (ATTR). For more
information, please visit www.eidostx.com.
About transthyretin amyloidosis (ATTR)
ATTR represents a significant unmet need of a comparatively
large patient population in the context of rare genetic diseases
with an inadequate current standard of care. There are three
distinct diseases that comprise the ATTR family: wild-type ATTR
cardiomyopathy (ATTRwt-CM), mutant ATTR cardiomyopathy (ATTRm-CM),
and ATTR polyneuropathy (ATTR-PN). The worldwide prevalence of each
disease is approximately 400,000 patients, 40,000 patients and
10,000 patients, respectively.
All three forms of ATTR are progressive and fatal. For patients
with ATTRwt-CM and ATTRm-CM, symptoms usually manifest later in
life (age 50+), with median survival of three to five years from
diagnosis. ATTR-PN either presents in a patient's early 30s or
later (age 50+), and results in a median life expectancy of five to
ten years from diagnosis. Progression of all forms of ATTR causes
significant morbidity, impacts productivity and quality of life,
and creates a significant economic burden due to the costs
associated with progressively greater patient needs for supportive
care.
About AG10
AG10 is an investigational, orally-administered small molecule
designed to potently stabilize tetrameric transthyretin, or TTR,
thereby halting at its outset the series of molecular events that
give rise to amyloidosis, or ATTR. In a Phase 2 clinical trial in
subjects with symptomatic ATTR-CM, AG10 was well tolerated and
increased serum TTR concentrations, a biomarker associated with
survival in an observational study of ATTRwt-CM patients, in a
dose-dependent manner. AG10 is currently being studied in an
open-label extension of a Phase 2 clinical trial in patients with
ATTR cardiomyopathy.
AG10 was designed to mimic a naturally-occurring variant of the
TTR gene (T119M) that is considered a “rescue mutation” because it
has been shown to prevent ATTR in individuals carrying pathogenic,
or disease-causing, mutations in the TTR gene. To our knowledge,
AG10 is the only TTR stabilizer in development that has been
observed to mimic the structure of this rescue mutation.
Media Contact:Carolyn Hawley Canale
Communications619-849-5382Carolyn@canalecomm.com
Investor Contact:Alex GrayBurns
McClellan212-213-0006agray@burnsmc.com
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Apr 2023 to Apr 2024